AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery - Trial NCT03965494
Access comprehensive clinical trial information for NCT03965494 through Pure Global AI's free database. This Early Phase 1 trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and is currently Recruiting. The study focuses on Brain and Central Nervous System Tumors. Target enrollment is 20 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Timeline & Enrollment
Early Phase 1
Jan 02, 2020
Dec 01, 2023
Primary Outcome
Proportion of patients who achieve a drug concentration at = 1.0 uM level in contrast enhancing tumor tissue
Summary
This phase I trial studies how well AXL inhibitor BGB324 works in treating participants with
 glioblastoma that has come back who are undergoing surgery. AXL inhibitor BGB324 may stop the
 growth of tumor cells by blocking some of the enzymes needed for cell growth.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT03965494
Non-Device Trial